Parkinson's Disease
University of Iowa Roy J. and Lucille A. Carver College of Medicine
This product is part of the GeriaFlix series at the University of Iowa. GeriaFlix are multidisciplinary presentations on topics in clinical geriatrics. Presented in a streaming digital video format with synchronized slides, each presentation lasts approximately 1 hour. In this lecture, Dr. Rodnitzky will describe the principal symptoms of Parkinson's disease and the spectrum treatments that have proven to be useful. He will also discuss the goals and complications of long-term therapy for Parkinson's.
This product is part of a series of digitized lectures devoted to topics in clinical geriatrics designed to teach important principles in the management of older persons. By using this lecture series, learners will be able to improve their overall knowledge about managing common geriatric syndromes; understand the unique health care needs of older patients, differences in the management of common clinical conditions, and how physiologic changes associated with aging impact management; develop a working knowledge of important legal and ethical issues associated with end-of-life care; and understand and apply principles of the multi-disciplinary geriatric assessment.
The learning objectives of this particular digitized presentation are:
- Learn the cardinal clinical signs of Parkinson's disease.
- Be familiar with the spectrum treatments that are useful in Parkinson's disease.
- Understand the complications of long-term therapy for Parkinson's disease.
For more information about the GeriaFlix series, go to http://www.healthcare.uiowa.edu/igec/resources-edu....
Comments
Dr. Rodnitzky delivered an interesting presentation on Parkinson's therapy. Deep brain stimulation (DBS) shows promise as a treatment modality in advanced cases particularly for those who are refractory to increasing levels of L-Dopa. This is evident by the fact that tremor, dyskinesia, rigidity and akinesia may be reduced in most patients receiving DBS. Unfortunately, hypokinetic speech and balance are worsened with this treatment indicating more research is needed in identifying which neurotransmitters target these actitivities.